- Dollar Amount of Shares Sold
- $12,212,448.60
- Number of Insider Stock Sales in the Last 180 Days
- 17
- Volume of Shares Sold
- 331,772
- Who Sold Shares
- Akshay Vaishnaw (Insider), Edward H Myles (CFO), Jay T Backstrom (CEO), Jeffrey S Flier (Director), Jing L Marantz (Insider), Joshua Reed (Director), Junlin Ho (General Counsel), Katie Peng (Director), Kristina Burow (Director), Michael Gilman (Director), Mo Qatanani (Insider) and Tracey Sacco (Insider)
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
More about Scholar Rock
